Clinical studies in unselected NSCLC-patient populations conducted with RET TKIs did not demonstrate particular survival benefits; however, case reports described promising therapeutic responses to both vandetanib and cabozantinib in patients with RET-fusion-positive lung adenocarcinomas [13, 31, 32]. This evidence concerns the gene RET and lung adenocarcinoma.